Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $98.60 | Total: $493.00 |
| 1 | 10 | $83.52 | Total: $835.20 |
| 1 | 25 | $70.76 | Total: $1,769.00 |
| 1 | 50 | $60.32 | Total: $3,016.00 |
| 1 | 100 | $52.20 | Total: $5,220.00 |
Overview
Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858RT790M), EGFR (d746-750), EGFR (d746-750T790M), respectively. Oritinib can be used in studies about the treatment of non-small cell lung cancer.
Chemical Properties
| Molecular Formula | C31H37N7O2 |
| Molecular Weight | 539.67 |
| CAS Numbers | 2035089-28-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c2CCCCn2c2ccccc12 |
Storage and Handling
0C Short Term, -20C Long Term
References
Luwei Han, et al. SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer. Front Pharmacol. 2021 Apr 27;12 665253.